No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VRPX Virpax Pharmaceuticals
- 0.6853
- -0.0184-2.61%
Close Jun 14 16:00 ET
- 0.6853
- 0.00000.00%
Post 17:22 ET
1.88MMarket Cap-47P/E (TTM)
0.7300High0.6820Low14.00KVolume0.6820Open0.7037Pre Close9.93KTurnover0.57%Turnover RatioLossP/E (Static)2.74MShares11.774052wk High-1.55P/B1.67MFloat Cap0.631652wk Low--Dividend TTM2.44MShs Float360.0000Historical High--Div YieldTTM6.82%Amplitude0.6310Historical Low0.7080Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Virpax Pharmaceuticals to Present at 2024 BIO International Convention
Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
Maxim Group Downgrades Virpax Pharmaceuticals(VRPX.US) to Hold Rating
Maxim Group analyst Naz Rahman downgrades $Virpax Pharmaceuticals(VRPX.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 29.7% and a total average return of -11.5% ov
Maxim Group Downgrades Virpax Pharmaceuticals to Hold
Maxim Group analyst Naz Rahman downgrades Virpax Pharmaceuticals from Buy to Hold.
Virpax Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 — Maxim Group Downgrades Buy → Hold 06/09/2022 471.43% Maxim Group → $4 Initiates Coverage On
SINTX Technologies SINT Earnings; Virpax Pharmaceuticals VRPX Earnings
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble
Virpax Pharmaceuticals (VRPX) shares tumbled more than 65% in recent Wednesday trading after the company priced its public offering of slightly more than 1.6 million common shares and related warrants
Comments
$Virpax Pharmaceuticals(VRPX.US$ Reuters· 1 min ago
Virpax Pharmaceuticals Inc - Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief
Virpax Pharmaceuticals Inc - Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief
6
$Virpax Pharmaceuticals(VRPX.US$
NEWS
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax Pharmaceuticals, Inc. announced the results of a Maximum Tolerated Dose (MTD) study for Probudur™, a long-acting liposomal bupivacaine formulation aimed at reducing the need for opioids after surgery. The study showed that Probudur provided both immediate and sustained pain relief at the wound site, with minimal toxicity and better therapeutic results compared to free bupivacaine....
NEWS
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax Pharmaceuticals, Inc. announced the results of a Maximum Tolerated Dose (MTD) study for Probudur™, a long-acting liposomal bupivacaine formulation aimed at reducing the need for opioids after surgery. The study showed that Probudur provided both immediate and sustained pain relief at the wound site, with minimal toxicity and better therapeutic results compared to free bupivacaine....
$Virpax Pharmaceuticals(VRPX.US$ Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
$Virpax Pharmaceuticals(VRPX.US$ Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research![]()
$Virpax Pharmaceuticals(VRPX.US$ The vote to effect a R/S was approved! Now waiting for date and exact amount![]()
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg